Printer Friendly

Botulinum toxin suppression of CNS network activity in vitro.

The botulinum toxins are potent agents which disrupt synaptic transmission. While the standard method for BoNT detection and quantification is based on themouse lethality assay,we have examined whether alterations in cultured neuronal network activity can be used to detect the functional effects of BoNT. Murine spinal cord and frontal cortex networks cultured on substrate integrated microelectrode arrays allowed monitoring of spontaneous spike and burst activity with exposure to BoNT serotype A (BoNT-A). Exposure to BoNT-A inhibited spike activity in cultured neuronal networks where, after a delay due to toxin internalization, the rate of activity loss depended on toxin concentration. Over a 30 hr exposure to BoNT-A, the minimum concentration detected was 2 ng/mL, a level consistent with mouse lethality studies. Asmall proportion of spinal cord networks, but not frontal cortex networks, showed a transient increase in spike and burst activity with exposure to BoNT-A, an effect likely due to preferential inhibition of inhibitory synapses expressed in this tissue. Lastly, prior exposure to human-derived antisera containing neutralizing antibodies prevented BoNT-A induced inhibition of network spike activity. These observations suggest that the extracellular recording from cultured neuronal networks can be used to detect and quantify functional BoNT effects.

1. Introduction

The botulinum neurotoxins (BoNTs), which are produced and secreted by the bacteria Clostridium, are considered the most lethal substances known [1]. There are seven BoNT serotypes (A--G), of which four (A, B, E, and F) are typically associated with human illness [2]. Linked by a disulfide bond, BoNTs consist of a 100 kDa heavy chain and a 50 kDa light chain which have distinct roles in toxicity. The heavy chain contains cell receptor binding and translocation fragments that enable BoNT uptake into cells, in particular neuronal synapses. Once within the cytosol, the catalytic light chain cleaves the solubleN-ethyl maleimide sensitive fusion protein receptors (SNAREs) that have a crucial role in exocytosis [3]. Specifically, BoNT serotype A (BoNT-A) targets the synapto-some-associated 25 kDa protein (SNAP25) [3]. The cleavage of this SNARE results in inhibition of vesicle fusion such that neurotransmitter release is impaired [3]. During illness usually associated with contaminated food consumption, BoNT can inhibit peripheral neuromuscular transmission critical for respiratory function thus requiring ventilator support [4]. However, due to the long term persistence of neurotransmission blockade, BoNT has found use in cosmetic applications, and more recently as therapeutic to treat a range of excitatory disorders including blepharospasm, muscle spasticity, migraines [5], and incontinence [6].

The standard method for BoNT detection and quantification is based on the mouse lethality assay [7] which can require days to complete. Other approaches are immunological and genetic-based which rely on structural features of the toxin or sequence of the pathogen (for review, [8, 9]). An alternative approach to detection of BoNT involves the use of cell- and tissue-based assays [10]. Assays have been developed based on SNARE cleavage using PC12 cells [11] and embryonic chick neurons [12]. Recent work with antibodies specific for SNAP-25 cleavage has reported BoNT-Adetection within cultured chicken spinal motoneurons [13], rat spinal cord neurons [14], mouse embryonic stem cell (ESC) derived neurons [15], and ESC derived motoneurons [16]. Quantification of these protein cleavage assays depends on destructive homogenization of tissue to allow binding and assessment.

In contrast, we have examined whether alterations in neuronal network activity can be used to detect the functional effects of BoNT-A. It has been well established that neurons cultivated on substrate-integrated microelectrode arrays (MEAs) form networks where extracellular action potentials or spikes can be monitored noninvasively to quantify the functional effects of neuroactive compounds [17-20]. In the present study, we demonstrate that exposure to pM concentrations of BoNT-A inhibits the spike activity in neuronal network biosensors in a concentration-dependent manner. Although the networks used were derived from mouse embryonic central nervous system tissue (both frontal cortex and spinal cord), the sensitivity data correlate well with published data based on peripheral cholinergic synapses. In addition, exposure to human-derived antisera containing neutralizing antibodies can prevent BoNT-A induced inhibition of network spike activity. These observations suggest that the extracellular recording from spontaneously active cultured neuronal networks can be used to detect and quantify functional BoNT effects and also to screen BoNT therapeutic targets.

2. Methods

2.1. Chemicals and Reagents. All experiments were performed with the neurotoxin alone without the associated complex. BoNT-A was purchased from Sigma in amounts of 100 ug/100 uL in 0.2 M NaCl and 0.05 M sodium acetate (Sigma B8776) for the majority of experiments E-1 to E-57. Subsequent experiments (E-58 to E-77) used toxin from WACO. BoNT-A human derived antisera were supplied by Dr. David E. Steele, Product Manager, Joint Vaccine Acquisition Program (JVAP, Fort Detrick, MD, USA). JVAP is responsible for managing efforts to develop vaccines to protect soldiers against biological agents.

2.2. Microelectrode Arrays and Cell Culture. The techniques used to fabricate and prepare microelectrode arrays have been described previously [20, 21]. The conductor patterns consisted of 64 electrodes arranged as either a single recording matrix [22] or a dual recording matrix configuration [23]. The later configuration allows cultivation of two age and maintenance-matched but separate networks, each growing on a 32 electrode recording matrix. The methyltrimethoxysilane resin insulation was activated by flaming through masks and coated with poly-D-lysine and laminin [24]. Frontal cortex tissues were dissociated from embryos of ICR mice at age of E16-17. Cortical tissue was minced mechanically, enzymatically digested with papain, triturated, combined with Dulbecco's modified minimal essential medium (DMEM), supplemented with 5% fetal bovine serum and 5% horse serum, and seeded at 70 K cells per 100 [micro]L on the MEA (~3mm diameter adhesion island). Spinal cord tissue was seeded in MEM with 10% fetal bovine and 10% horse serum. After 2-3 days, the FC and SC cultures were transitioned to DMEM or MEM, respectively, containing 5% horse serum supplemented with 2% B-27 (Gibco-Life Technologies, Grand Island, NY, USA). Cultures were maintained at 37[degrees]C in a 10% [CO.sub.2] atmosphere, and given half medium changes biweekly. This procedure generally yielded networks with 300-500 neurons per [mm.sup.2] over the electrode array. For several experiments, we utilized dual network substrates where sister networks were grown on 3 mm diameter adhesion islands centered on the 1 mm diameter recording matrix featuring 32 microelectrodes. Sister networks were seeded from the same cell pool at the same time and maintained under the same medium (confined by a single silicone gasket) for several weeks until the time of recording chamber assembly. Such dual network systems provide good controls and reliable comparisons between different test compound concentrations. For single and dual network MEAs, the resulting neuronal networks can remain spontaneously active and pharmacologically responsive for several months [25, 26].

2.3. Extracellular Recording. MEAs were incorporated into a recording apparatus that included a stainless steel chamber block with Luer connections, a base plate with power resistors to maintain temperature at 37 [+ or -] 1 [degrees]C, and a cap with heated ITO-coated glass to prevent condensation and allow microscope observation during recording. The pH was maintained at 7.4 [+ or -] 0.1 by passing a stream of 10% [CO.sub.2] in air (~10 mL/min) through the chamber cap. To compensate for water evaporation, osmolarity was maintained at 320 mosmol/kg by the addition of ultrapure water via a syringe pump (~50 [micro]L/hr). The 64 contacts of the MEA were connected to a Multichannel Acquisition Processor system (Plexon Inc., Dallas TX, USA) consisting of 64 preamplifiers connected to the MEA via zebra strips (Fujipoly America Corp, Cartaret, NJ, USA) and second stage amplifiers with 64 digital signal processors (DSPs). A signal-to-noise ratio of 2 : 1 or better was used as a criterion for selecting action potentials based onwave shape templates. Under optimal conditions, up to 4 wave shapes can be discriminated per DSP in real time.

2.4. Response Quantification and Controls. Network spike and burst production were quantified as described previously [18, 20, 27]. Spike and burst rates were plotted as mean values per minute, which allowed an effective visualization of network activity evolution during the entire experiment. Each minute, the total activity was divided by the active channels. An active channel was defined as one with at least 10 discriminated spike signals per minute. For each network, activity changes were normalized as percent decreases from a network-specific reference activity that was maintained in a stable state for at least 0.5 to 1 hr. Although networks can have different levels of spontaneous activity, the use of the internal reference results in highly reproducible pharmacological responses [18, 23, 28-32] and even allows calculation of dissociation constants [33].The reference is either native activity (i.e., activity recorded prior to application of any compound) or a stable reference state under a constant additive, such as bicuculline, which was used in ~60% of the experiments to increase activity and stabilize the minute mean profile. The application of this competitive blocker of the GABA type A receptor did not appear to have any influence on the time course of the activity loss.

Figure 1 shows a typical activity profile in response to 25 ng/mL BoNT-A applied to the network after recording 32 min of reference activity (Reference). The average network activity drops to 10%, 50%, and 90% at 102, 180, and 378 min, respectively. Values were determined visually from spike rate plots using NEX displays (NEX Technologies, Madison, AL, USA).

2.5. Burst Identification by Simulated RC Integration. After spike discrimination using wave shape templates (Plexon Inc.), the time stamps were integrated using an integration constant of 70 ms. Bursts were identified by two thresholds: T1 at a level close to the noise and T2 at 5x threshold to determine whether a T1 signal was indeed a burst. A single threshold is not sufficient as a low threshold often includes noise and a high threshold delays burst onset times. Because burst termination is biased by the decay constant (Figure 2), a 10ms adjustment was made to "snap" the profile closer to the first and last spikes of the burst. A gap time of 100 ms was used to separate bursts. If activity remained below T1 for more than 100 ms, two bursts were generated. The gap time was adjustable and selection depended on the overall spike pattern provided by the display of time stamp patterns in NeuroExplorer (NEX Technologies).

2.6. Addition of Test Compounds. All experiments were performed in CNNS stainless steel chambers featuring two Luer-Luer ports connected to 1 mm diameter conduits that are opened 0.5 mm above the MEA surface inside the "O"-ring domain of the constant 2 mL medium bath [22] The design allowed sterile test compound additions without lifting the chamber cap. Antisera were heat-inactivated (30 min at 56[degrees]C) and filtered with a 0.2 [micro]m syringe filter. Usually 40[micro]L was mixed with 500 uL medium from the culture bath, vortexed, and re-introduced to the culture via the Luer ports. For most BoNT-A additions, approximately 0.5 mL of medium was slowly removed from the chamber via a 3 mL syringe.The test compound (2 to 20 [micro]L) was introducedwith pipette tips to the end of the syringe and sucked in. The syringe was reattached to the Luer port and a further 0.3 to 0.5 mL of medium was withdrawn. Air bubbles were used to mix the medium in the syringe. The mixture was then re-introduced to the medium bath through the same Luer port.

3. Results

3.1. Activity Decay as a Function of Concentration and Time. A total of 77 experiments were performed with BoNT-A. Of these, 27 spinal cord cultures and 13 frontal cortex cultures were used to quantify the effect of the toxin on synapses of the central nervous system. The remaining 21 experiments were either failures due to excessive network instability (n = 7) and technical problems (n = 5), or the responses exhibited biphasic responses which limited the utility of the data for time/activity decay quantification (n = 9). The remaining 16 networks were used for testing antisera. Ages for all networks ranged from 25 to 101 days in vitro (DIV) with an average of 39 and a median of 33 DIV. As demonstrated in many publications [33-35], these cultures display spontaneous activity primarily in the form of coordinated (but not synchronized) bursts. In general, the native activity patterns of spinal cord networks aremore complex than that of the cortical networks with the former displaying more complex burst patterns and longer burst durations [36, 37]. Numerous experiments have also demonstrated that, with proper life support and optical monitoring, networks can be maintained viable in recording chambers on the microscope stage for over one week with relative stability of mean spike and burst rates [28, Figures 14 and 15].

Exposure to BoNT-A at various concentrations resulted in a time-dependent inhibition of both spike and burst generation. In Figure 3, application of 50 ng/mL resulted in a gradual activity decay after a latency of 60 min. The loss of spike and burst activity was tightly coupled for 400 min when all bursting ceased with some residual spiking remaining. The activity inhibition was seen in spinal cord (Figure 4(a)) as well as frontal cortex cultures (Figure 4(b)). Although the general characteristics of the profiles are the same, the profile shapes vary, with higher concentrations inducing a faster decay profile. While the variability of the one minute averages introduces some uncertainties in the precise measurement of activity loss, the temporal evolution of inhibition is clearly a function of BoNT-A concentration. For example, the responses at 500 min and 290 min correspond to 90% activity decreases for the 12 ng/mL and the 100 ng/mL of BoNT-A, respectively. Similar effects are seen from a dual network frontal cortex experiment exposed to 50 and 100ng/mL BoNT-A at the same time (Figure 4(c)). After an incubation period of approximately 60 min, neuronal network activity begins to decrease to a virtually quiescent state of minimal spike activity. The BoNT-A-induced rate of decrease in mean spike rate was greater at 100 ng/mL than at 50 ng/mL.

3.2. Response Data Quantification from Frontal Cortex and Spinal Cord Networks. Activity decreases in frontal cortex networks as a function of concentration are summarized in Figure 5(a) for the 10%, 50%, and 90% activity loss levels. In a log-log plot, the data are relatively linear and allow a determination of how long it will take to reach a particular activity decrease as a function of concentration. For example, a 90% activity loss with exposure to 2 ng/mL requires 32 hrs, whereas the same level of activity loss at 100 ng/mL requires only 3 hrs. Below 2ng/mL, the functions are not defined as no clear responses have been observed in this concentration range. Figure 5(b) shows the corresponding log-log plot for spinal cord networks. Differences are apparent in BoNT-A sensitivity and slopes between the tissue types. For example, when exposed to 50 ng/mL, the time durations corresponding to 10% and 50% inhibitionwere significantly reduced (P < 0.05) for frontal cortex versus spinal cord. Still, a comprehensive analysis of decay times for the two tissue types will require additional data.

3.3. Biphasic Responses. A surprising observation was the emergence of biphasic responses. A biphasic response was identified only if average network activity rose by 20% or more over the reference level. Among the experiments performed, which include 27 spinal cord and 13 frontal cortex cultures, biphasic responses were not prominent in cortical cultures whereas 22% of the spinal cord networks showed a clear biphasic response with exposure to BoNT-A. While this phenomenon was clearly tissue-specific, subpopulation analyses showed biphasic individual neuronal responses could be distinguished in cortical networks, albeit at a low level that did not affect the averaged minute-mean profiles. An example of a spinal cord network biphasic response is shown in Figure 6 where exposure to BoNT-A produced a 200% increase in spike activity over baseline and a 330% increase in bursting, followed by an exponential activity decay of more than 95%. As was always the case with BoNT-A exposure bursting appeared to show a more rapid decline than mean spike rate. In general, burst rates also show less variability. In the case of biphasic responses, neither profile shape nor time to peak activity allowed quantification as a function of BoNT concentration.

3.4. Protective Effects of Human Antisera In Vitro. Human BoNT-A antisera were tested by preadministration (usually 20-40min) to the culture bath before addition of BoNT-A. Sixteen experiments were performed with human BoNT-A antisera. Of these experiments, six networks were lost due to serum toxicity which stopped all spontaneous activity. Such experiments were discontinued and no quantification of cytotoxicity was attempted. The remaining four spinal cord and six frontal cortex networks were subjected to serum concentrations ranging from 0.2% to 5% (Table 1). All protective effects of antisera occurred at concentrations above 1%. Representative data are shown in Figure 7 where the normal BoNT-A-induced inhibition of mean spike and burst rates was prevented for a period of 40 hrs despite increasing the concentration from 50 to 250 ng/mL during the course of the experiment. Normally, the addition of 50 ng/mL BoNT-A stopped 90% of the spontaneous network activity in approximately 4 hrs (see Figure 4). Such a loss of activity does not occur in the presence of certain antisera, directly demonstrating protection against BoNT-A. Increasing concentrations of BoNT-A eventually overwhelm the protective effects of the antisera.

4. Discussion

Because the blood brain barrier protects the CNS from the BoNT toxin, research efforts have focused on cholinergic peripheral synapses.However, the clostridial toxins appear to affect all synapses [38, 39].For purposes of rapidscreening for efficacy of the toxins or antisera, peripheral nervous system preparations are labor intensive and require a large number of animals. This study was designed to show that neuronal networks in culture, derived fromthe central nervous system of mice, provide simple, reliable test beds for quantitative studies of BoNT-A. In addition, we show that cultured neuronal networks can be used to examine the protective effects of human antisera directed against BoNT-A.

The neuronal network activity decrease with exposure to BoNT-A is clearly a function of concentration and time. Bursting and spiking were generally tightly coupled in the native state. However, burst rate decay preceded spike decay under BoNT-A, and even after complete cessation of bursting, residual weak spiking often remained. Coordinated spontaneous activity in cultured neuronal networks is critically dependent on synaptic function, and our results are consistent with previous work demonstrating inhibition of neurotransmission by BoNT-A exposure in cultured hippocampal excitatory neurons [39] and embryonic stem cell derived neurons [15]. Cultured neuronal networks are composed of a heterogeneous mixture of excitatory and inhibitory neurons.

Responses of the networks to toxins and pharmacological agents depend on the tissue of origin, reflect histotypic differences observed in vivo, and can result in differential effects of the same compound across network tissue types. While the mouse frontal cortex expresses SNAP-25 isoforms [40], it may be that excitatory neurons preferentially express SNAP-25 [39] such that the effect of BoNT-A is to reduce bursting and spike activity in this tissue type. In contrast, the biphasic responses seen in spinal cord networks may be a reflection of disinhibition where inhibitory neurons are affected more rapidly because of greater sensitivity. The observation that spinal cord networks are more prone to show such responses may reflect a differential sensitivity of glycinergic inhibitory pathways. Indeed, it has already been observed that spinal cord synapses differ in their sensitivity to BoNT with a ranking of glycinergic > GABAergic [much greater than] glutamatergic [41]. The fact that biphasic responses are not observed in all networks may reflect variable degrees of influence of inhibitory circuits, particularly glycinergic, in cultures derived from different tissue types.

Our findings are limited to concentrations at and above 2 ng/mL. Below this concentration, no overt changes in spike production were detected in a 24 hr period. Concentrations below 2 ng/mL were explored by Scarlatos et al. [42], where only subtle but statistically significant effects on burst duration and the number of spikes/bursts emerged after 48 hr of BoNT-A exposure to 0.2 ng/mL. Our focus was to show activity termination as a function of concentration and time, which required higher concentrations.

The majority of prior studies of BoNT action with neuronal cultures have relied on western blots to assess SNARE cleavage [13, 14, 16, 43]. These papers report BoNT-A sensitivity in the range of 20-500 pM, which compares favorably to the sensitivity limit of 2 ng/mL or 13 pM observed with neuronal network biosensors. Note that Fernandez-Salas and colleagues [44] recently reported a cell based protein cleavage assay using differentiated human neuroblastoma SiMa cells that showed sensitivity to BoNT-A at concentrations as low as 1 pM. In contrast to the present findings, other function-based biosensor strategies such as cellular metabolism [45] or micromechanical sensing from intact cells [46] exhibit BoNT-A sensitivity in the nM range. Furthermore, note that neuromuscular junction preparations and mouse LD50 concentrations range from 10 pM[47] to 0.2 picoMoles (~20 pM; [48]). Two prior studies have reported higher sensitivity to BoNT-A at 33 fM [49] and 400fM [15], although the physiological significance of low levels of protein cleavage to the exocytotic process is unclear. In spite of the high sensitivity that can be achieved by cleavage assays, these approaches are destructive, requiring cell lysis and processing at each exposure time point. In contrast, the neuronal network biosensors rely on noninvasive extracellular recording yielding a continuous recording of the electrical activity related to synaptic function in a dynamically active system.

Prior studies have shown that exposure of BoNT-A poisoned tissue to 4-aminopyridine (4-AP) can rescue neuromuscular transmission [50]. Similar observations were also made by Akaike et al. [41] who found the 4-AP as well as high [K.sup.+] rescued neurons from BoNT-induced suppression of synaptic transmission.The putative basis of this rescue effect is an increase of presynaptic action potential duration with 4-AP which results in greater synaptic calcium influx and enhanced exocytosis [51]. In a subset of pilot experiments, we applied 100 [micro]M 4-AP to networks where spike and burst activity had been greatly diminishedwith exposure to BoNTA. We observed a transient recovery of spike activity which is consistent with prior studies [41]. It appears that a transmission-weakened network from exposure to BoNT-A can shift from quiescence to limited activity when synaptic excitation is enhanced. Future studies will be necessary to quantify such recovery over longer periods of time and search for potential therapeutic applications.

In summary,we have demonstrated the utility of neuronal network biosensors for detection of BoNT-A. Furthermore, preliminary data showed that the networks can tolerate exposure to human antisera and that this intervention suppresses the biosensor response to the toxin. Unlike other cell-based assay formats which are tailored for cleavage of a specific protein, neuronal networks can be readily used for detection of a range of BoNT serotypes which target different proteins to affect transmission.The major advantage of this approach over other cell-basedmethods is the continuous monitoring of synaptic function reflected by multisite extracellular spike and burst activity.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


All experiments were conducted at CNNS at the University of North Texas and supported by the Charles Bowen Memorial Endowment to the CNNS, by a research subcontract from the Joint Vaccine Acquisition Program (JVAP), Frederick, MD, and by a DARPA contract from the Activity Detection Technology Program. The authors thank Anthony Curran for cell-culture support, Tracy Howard for MEA fabrication support, and Bret Zim, George Haidar, and Dr. Lisa Rosenberg for participation in early experiments.


[1] L. L. Simpson, "Identification of the major steps in botulinum toxin action," Annual Review of Pharmacology and Toxicology, vol. 44, pp. 167-193, 2004.

[2] J.M. Rusnak and L. A. Smith, "Botulinum neurotoxin vaccines: past history and recent developments," Human Vaccines, vol. 5, no. 12, pp. 794-805, 2009.

[3] Y. Humeau, F. Doussau, N. J. Grant, and B. Poulain, "How botulinum and tetanus neurotoxins block neurotransmitter release," Biochimie, vol. 82, no. 5, pp. 427-446, 2000.

[4] K. G. Devers and J. S. Nine, "Autopsy findings in botulinum toxin poisoning," Journal of Forensic Sciences, vol. 55, no. 6, pp. 1649-1651, 2010.

[5] D. D. Truong and W. H. Jost, "Botulinum toxin: clinical use," Parkinsonism and Related Disorders, vol. 12, no. 6, pp. 331-355, 2006.

[6] A. K. Patel, J.M. Patterson, and C.R. Chapple, "Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results," European Urology, vol. 50,no. 4, pp. 684-710, 2006.

[7] E. J. Schantz and E. A. Johnson, "Dose standardisation of botulinum toxin," The Lancet, vol. 335, no. 8686, p. 421, 1990.

[8] A. Scarlatos, B. A. Welt, B. Y. Cooper, D. Archer, T. DeMarse, and K. V. Chau, "Methods for detecting botulinum toxin with applicability to screening foods against biological terrorist attacks," Journal of Food Science, vol. 70, no. 8, pp. R121-R130, 2005.

[9] J. W. Grate, R. M. Ozanich, M. G. Warner, J. D. Marks, and C. J. Bruckner-Lea, "Advances in assays and analytical approaches for botulinum-toxin detection," Trends in Analytical Chemistry, vol. 29, no. 10, pp. 1137-1156, 2010.

[10] R. M. Hakami, G. Ruthel, A. M. Stahl, and S. Bavari, "Gaining ground: assays for therapeutics against botulinum neurotoxin," Trends in Microbiology, vol. 18, no. 4, pp. 164-172, 2010.

[11] M. Dongo, W. H. Tepp, E. A. Johnson, and E. R. Chapman, "Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 41, pp. 14701-14706, 2004.

[12] A.M. Stahl, G. Ruthel, E. Torres-Melendez, T. A. Kenny, R. G. Panchal, and S. Bavari, "Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: implications for therapeutic discovery," Journal of Biomolecular Screening, vol. 12, no. 3, pp. 370-377, 2007.

[13] J. E. Nuss, G. Ruthel, L. E. Tressler et al., "Development of cell-based assays to measure botulinum neurotoxin serotype A activity using cleavage-sensitive antibodies," Journal of Biomolecular Screening, vol. 15, no. 1, pp. 42-51, 2010.

[14] S. Pellett, W.H. Tepp, S. I. Toth, and E. A. Johnson, "Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination," Journal of Pharmacological and Toxicological Methods, vol. 61, no. 3, pp. 304-310, 2010.

[15] P. McNutt, J. Celver, T. Hamilton, and M. Mesngon, "Embryonic stem cell-derived neurons are a novel, highly sensitive tissue culture platform for botulinum research," Biochemical and Biophysical Research Communications, vol. 405, no. 1, pp. 85-90, 2011.

[16] E. Kiris, J. E. Nuss, J. C. Burnett et al., "Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery," Stem Cell Research, vol. 6, no. 3, pp. 195-205, 2011.

[17] G. W. Gross, B. K. Rhoades, H. M. E. Azzazy, and M.-C. Wu, "The use of neuronal networks on multielectrode arrays as biosensors," Biosensors and Bioelectronics, vol. 10, no. 6-7, pp. 553-567, 1995.

[18] E. W. Keefer, A. Gramowski, D. A. Stenger, J. J. Pancrazio, and G. W. Gross, "Characterization of acute neurotoxic effects of trimethylolpropane phosphate via neuronal network biosensors," Biosensors & Bioelectronics, vol. 16, no. 7-8, pp. 513-525, 2001.

[19] J. J. Pancrazio, Y. S. Shubin, N. Kulagina et al., "A portable microelectrode array recording system incorporating cultured neuronal networks for neurotoxin detection," Biosensors and Bioelectronics, vol. 18, no. 11, pp. 1339-1347, 2003.

[20] G. W. Gross, "Simultaneous single unit recording in vitro with a photoetched laser deinsulated gold multimicroelectrode surface," IEEE Transactions on Biomedical Engineering, vol. 26, no. 5, pp. 273-279, 1979.

[21] G.W. Gross, W. Y. Wen, and J.W. Lin, "Transparent indium-tin oxide electrode patterns for extracellular, multisite recording in neuronal cultures," Journal of Neuroscience Methods, vol. 15, no. 3, pp. 243-252, 1985.

[22] G.W. Gross and F.U. Schwalm, "A closed flow chamber for long-term multichannel recording and optical monitoring," Journal of Neuroscience Methods, vol. 52, no. 1, pp. 73-85, 1994.

[23] A. F. M. Johnstone, G.W. Gross, D. G. Weiss, O. H.-U. Schroeder, A. Gramowski, and T. J. Shafer, "Microelectrode arrays: a physiologically based neurotoxicity testing platform for the 21st century," NeuroToxicology, vol. 31, no. 4, pp. 331-350, 2010.

[24] J. H. Lucas, L. E. Czisny, and G.W. Gross, "Adhesion of cultured mammalian central nervous systemneurons to flame-modified hydrophobic surfaces," In Vitro Cellular & Developmental Biology, vol. 22, no. 1, pp. 37-43, 1986.

[25] G. W. Gross, "Internal dynamics of randomized mammalian neuronal networks in culture," in Enabling Technologies for Cultured Neural Networks, D. A. Stenger and T. M. McKenna, Eds., pp. 277277-317317, Academic Press, New York, NY, USA, 1994.

[26] S. M. Potter and T. B. DeMarse, "A new approach to neural cell culture for long-term studies," Journal of Neuroscience Methods, vol. 110, no. 1-2, pp. 17-24, 2001.

[27] S. I. Morefield, E. W. Keefer, K. D. Chapman, and G. W. Gross, "Drug evaluations using neuronal networks cultured on microelectrode arrays," Biosensors and Bioelectronics, vol. 15, no. 7-8, pp. 383-396, 2000.

[28] G. W. Gross and J. J. Pancrazio, "Neuronal network biosensors," in Smart Biosensor Technology, G. K. Knopf and A. S. Bassi, Eds., pp. 177-201, CRC & Taylor & Francis, Boca Raton, Fla, USA, 2007.

[29] Y. Xia and G. W. Gross, "Histiotypic electrophysiological responses of cultured neuronal networks to ethanol," Alcohol, vol. 30, no. 3, pp. 167-174, 2003.

[30] T. J. Shafer, S. O. Rijal, and G. W. Gross, "Complete inhibition of spontaneous activity in neuronal networks in vitro by deltamethrin and permethrin," NeuroToxicology, vol. 29, no. 2, pp. 203-212, 2008.

[31] C. Wu, K. Gopal, G. W. Gross, T. J. Lukas, and E. J. Moore, "An in vitro model for testing drugs to treat tinnitus," European Journal of Pharmacology, vol. 667, no. 1-3, pp. 188-194, 2011.

[32] K. V. Gopal, C. Wu, B. Shrestha, K. C. M. Campbell, E. J. Moore, and G. W. Gross, "D-Methionine protects against cisplatin-induced neurotoxicity in cortical networks," Neurotoxicology and Teratology, vol. 34, no. 5, pp. 495-504, 2012.

[33] S.O. Rijal and G. W. Gross, "Dissociation constants for GABAA receptor antagonists determined with neuronal networks on microelectrode arrays," Journal of Neuroscience Methods, vol. 173, no. 2, pp. 183-192, 2008.

[34] D. A. Wagenaar, J. Pine, and S. M. Potter, "An extremely rich repertoire of bursting patterns during the development of cortical cultures," BMC Neuroscience, vol. 7, article 11, 2006.

[35] M. H. Droge, G. W. Gross, M. H. Hightower, and L. E. Czisny, "Multielectrode analysis of coordinated, multisite, rhythmic bursting in cultured CNS monolayer networks," Journal of Neuroscience, vol. 6, no. 6, pp. 1583-1592, 1986.

[36] L. Turnbull, E. Dian, and G. Gross, "The string method of burst identification in neuronal spike trains," Journal of Neuroscience Methods, vol. 145, no. 1-2, pp. 23-35, 2005.

[37] G. W. Gross and K. V. Gopal, "Emerging histiotypic properties of cultured neuronal networks," in Advances in Network Electrophysiology Using Multi-Electrode Arrays, M. Taketani and M. Baudry, Eds., pp. 193-214, Springer, New York, NY,USA, 2006.

[38] E. Habermann, "Inhibition by tetanus and botulinum A toxin of the release of [3H]noradrenaline and [3H]GABA fromrat brain homogenate," Experientia, vol. 44, no. 3, pp. 224-226, 1988.

[39] C. Verderio, C. Grumelli, L. Raiteri et al., "Traffic of botulinum toxins A and E in excitatory and inhibitory neurons," Traffic, vol. 8, no. 2, pp. 142-153, 2007.

[40] S. Yamamori, M. Itakura, D. Sugaya, O. Katsumata, H. Sakagami, and M. Takahashi, "Differential expression of SNAP-25 family proteins in the mouse brain," Journal of Comparative Neurology, vol. 519, no. 5, pp. 916-932, 2011.

[41] N. Akaike, Y. Ito, M.-C. Shin et al., "Effects of A2 type botulinum toxin on spontaneous miniature and evoked transmitter release from the rat spinal excitatory and inhibitory synapses," Toxicon, vol. 56, no. 8, pp. 1315-1326, 2010.

[42] A. Scarlatos, A. J. Cadotte, T. B. De Marse, and B. A. Welt, "Cortical networks grown on microelectrode arrays as a biosensor for botulinum toxin," Journal of Food Science, vol. 73, no. 3, pp. E129-E136, 2008.

[43] L.C. Williamson, J. L. Halpern, C. Montecucco, J. E. Brown, and E. A. Neale, "Clostridial neurotoxins and substrate proteolysis in intact neurons: botulinum neurotoxin C acts on synaptosomal-associated protein of 25 kDa," Journal of Biological Chemistry, vol. 271, no. 13, pp. 7694-7699, 1996.

[44] E. Fernandez-Salas, J. Wang, Y. Molina, J. B. Nelson, B. P. S. Jacky, and K. R. Aoki, "Botulinum neurotoxin serotype a specific cell-based potency assay to replace the mouse bioassay," PLoS One, vol. 7, Article IDe49516, 2012.

[45] S. E. Eklund, R. G. Thompson, R. M. Snider et al., "Metabolic discrimination of select list agents by monitoring cellular responses in a multianalyte microphysiometer," Sensors, vol. 9, no. 3, pp. 2117-2133, 2009.

[46] V. Parpura and E. R. Chapman, "Detection of botulinum toxins: micromechanical and fluorescence-based sensors," Croatian Medical Journal, vol. 46, no. 4, pp. 491-497, 2005.

[47] A. W. Clark, S. Bandyopadhay, and B. R.DasGupta, "The plantar nerves-lumbrical muscles: a useful nerve-muscle preparation for assaying the effects of botulinum neurotoxin," Journal of Neuroscience Methods, vol. 19, no. 4, pp. 285-295, 1987.

[48] L. B. Pearce, E. R. First, R. D. Maccallum, and A. Gupta, "A pharmacologic characterization of botulinumtoxin for basic science and medicine," Toxicon, vol. 35, no. 9, pp. 1373-1412, 1997.

[49] S. Pellett, W. H. Tepp, C. M. Clancy, G. E. Borodic, and E. A. Johnson, "A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies," FEBS Letters, vol. 581, no. 25, pp. 4803-4808, 2007.

[50] L. L. Simpson, "A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism," Infection and Immunity, vol. 52, no. 3, pp. 858-862, 1986.

[51] M. Capogna, R. Anne McKinney, V. O'Connor, B. H. Gahwiler, and S. M. Thompson, "[Ca.sup.2+] or [Sr.sup.2+] partially rescues synaptic transmission in hippocampal cultures treated with botulinum toxin A and C, but not tetanus toxin," Journal of Neuroscience, vol. 17, no. 19, pp. 7190-7202, 1997.

(1) Department of Bioengineering, George Mason University, 4400 University Drive, Fairfax, VA 22030, USA

(2) Department of Speech and Hearing Sciences and CNNS, University of North Texas, Denton, TX 76203, USA

(3) Plexon Inc., Dallas, TX 75206, USA

(4) Department of Biological Sciences and Center for Network Neuroscience (CNNS), University of North Texas, Denton, TX 76203, USA

Correspondence should be addressed to Joseph J. Pancrazio;

Received 20 July 2013; Accepted 22 October 2013; Published 12 February 2014

Academic Editor: Anthony DeCaprio

Copyright [c] 2014 Joseph J. Pancrazio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

TABLE 1: Antisera protection experiments.

Experiment  Tissue         Age           #    Conc.    Delay     BoNT-A
            type           (d.i.v.)                              (ng/mL)

BT-016      SC             86            76   0.3%     0.3 h     100
BT-017      FC             28            32   1.0%     1.1 h     100
BT-019      FC             52            83   5%       0.4 h     100
BT-068      FC             33            4    5%       20 h      50
BT-070      FC             40            4    1.3%     3.0 h     50
BT-072      SC             29            4    0.5%     1.2 h     50
BT-074      SC             36            4    1%       4.2 h     50
BT-075      SC             37            23   1%       2.3 h     50
BT-076      FC             39            23   2%       0.7 h     50
BT-077a     FC             40            23   2%       0.3 h     50
BT-077b     Continuation                                         100
BT-077C     Continuation                                         150
BT-077d     Continuation                                         200

Experiment  Protection Yes/No   Experiment duration (h)

BT-016      No                  18
BT-017      No                  8
BT-019      Yes                 19
BT-068      Yes                 50
BT-070      Yes                 15
BT-072      No                  21
BT-074      No                  18.3
BT-075      No                  16.8
BT-076      Yes                 20
BT-077a     Yes                 15.2
BT-077b     Yes
BT-077C     Yes
BT-077d     Yes                 45

FC: frontal cortex; SC: spinal cord.
Delay: time between serum addition and BoNT-A addition.
COPYRIGHT 2014 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Pancrazio, Joseph J.; Gopal, Kamakshi; Keefer, Edward W.; Gross, Guenter W.
Publication:Journal of Toxicology
Article Type:Report
Date:Jan 1, 2014
Previous Article:In vitro reporter assays for screening of chemicals that disrupt androgen signaling.
Next Article:Micro- and macroelemental composition and safety evaluation of the nutraceutical Moringa oleifera leaves.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |